Plasma Epstein–Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma

Diagnostic significance of DNA and antibodies against capsid antigens of anti-Epstein–Barr virus antibodies levels in blood plasma of nasopharyngeal carcinoma patients from non-endemic region

“…При этом в плазме крови пациентов с ДОПР и здоровых лиц уровни ДНК ВЭБ не превышали фоновых значений. Полученные нами результаты совпадают с данными, опубликованными Y. M. Lo et al [22] и другими иссле-дователями [23,24,29], обнаружившими высокий уро-вень содержания ДНК ВЭБ в плазме крови пациентов РНГ из эндемичных регионов и предложившими ис-пользовать этот тест для диагностики и мониторинга этих больных.…”

“…В работах Y. M. Lo и других авторов [23,24,29] ВЭБ в плазме (сыворотке) больных РНГ, у которых регистрировали рецидив опухоли.…”

Prognostic role of plasma Epstein-Barr virus DNA load for nasopharyngeal carcinoma: a meta-analysis

“…The remaining 57 were fully evaluated for inclusion and 41 were eliminated for not reporting the outcomes of interest, reporting data that could not be pooled for a meta-analysis, not being relevant or reporting findings from a study that was already included. Sixteen studies were included in the study with a total of 7698 patients [12,13,[28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Three of the studies were retrospective in design and the remaining 13 studies were prospective (Table 1).…”

Beating 'Guangdong cancer': a review and update on nasopharyngeal cancer

“…[29][30][31][32][33][34][35][36] Recently Lee et al 37 demonstrated that serial post−intensity modulated radiation therapy (IMRT) undetectable plasma EBV DNA was prognostic of all predefined survival end-points at 3 years in the modern IMRT era. Leung et al 38 EBV DNA level at midcourse of radiotherapy (RT) or chemoradiotherapy (CRT) is adversely associated with worse overall survival (OS) and progressionfree survival (PFS). This suggests the possibility of shifting prognostication from a post-therapy timepoint to midcourse of therapy, and selecting highrisk patients for therapy intensification by measuring midcourse plasma EBV DNA level.…”

“…This suggests the possibility of shifting prognostication from a post-therapy timepoint to midcourse of therapy, and selecting highrisk patients for therapy intensification by measuring midcourse plasma EBV DNA level. 38 Another notable application is the prediction of treatment outcome by measuring the clearance rate of plasma EBV DNA. Following the observation that EBV DNA was rapidly cleared from the circulation after surgical resection of NPC, 39 subsequent studies demonstrated that patients with more rapid clearance of plasma EBV DNA responded better to chemotherapy or CRT compared with patients with a slower clearance.…”